Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Semax + Selank Stack
Also known as: Nootropic Peptide Stack
The Semax + Selank combination pairs two Russian-developed neuropeptides for cognitive enhancement. Semax is derived from ACTH and targets BDNF, while Selank is derived from tuftsin and targets anxiety and immune function.
Risk Level
Low RiskDifficulty
Intermediate| Class | Peptide |
| Category | Other Performance Compounds |
Mechanism of Action
Semax increases BDNF and NGF expression, enhancing neuroplasticity and cognitive function. Selank modulates GABA and serotonin systems, reducing anxiety while supporting immune function. Together they theoretically provide both cognitive stimulation and anxiolysis without the trade-offs of traditional stimulants.
Dosing Research
Semax: 200-600 mcg intranasally, 1-2x daily. Selank: 250-500 mcg intranasally, 1-2x daily. Both compounds have relatively short durations requiring multiple daily doses. Cycles typically 2-4 weeks.
Side Effects & Risks
Both compounds have favorable safety profiles individually in Russian clinical use. Semax may cause irritability or insomnia. Selank may cause mild sedation. No data on long-term combined use. Nasal irritation possible with intranasal administration.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.